Sanofi - ADR (SNY): Price and Financial Metrics
Sanofi - ADR (SNY)
Today's Latest Price: $49.69 USD
Updated Jan 22 6:55pm
Add SNY to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
SNY Stock Summary
- With a market capitalization of $124,605,290,489, Sanofi has a greater market value than 98.24% of US stocks.
- With a year-over-year growth in debt of 54.84%, Sanofi's debt growth rate surpasses 83.04% of about US stocks.
- In terms of volatility of its share price, SNY is more volatile than merely 0.39% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Sanofi are LIN, AZN, RTX, CAT, and IBM.
- SNY's SEC filings can be seen here. And to visit Sanofi's official web site, go to www.sanofi.com.
SNY Stock Price Chart Interactive Chart >
SNY Price/Volume Stats
| Current price | $49.69 | 52-week high | $55.00 |
| Prev. close | $49.64 | 52-week low | $37.62 |
| Day low | $49.36 | Volume | 3,099,100 |
| Day high | $50.02 | Avg. volume | 3,171,507 |
| 50-day MA | $49.21 | Dividend yield | 2.35% |
| 200-day MA | $49.88 | Market Cap | 124.43B |
Sanofi - ADR (SNY) Company Bio
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.
SNY Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $49.69 | $58.27 | 17% |
We started the process of determining a valid price forecast for Sanofi with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Sanofi ranked in the 55th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 17.83%. In terms of the factors that were most noteworthy in this DCF analysis for SNY, they are:
- The stock's equity weight, or the proportion of capital from equity relative to debt, is 69. Its equity weight surpasses that of only 19.54% of free cash flow generating stocks in the Healthcare sector.
- Sanofi's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 6.21% of tickers in our DCF set.
- SNY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than only 6.21% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 15% |
| 1% | 16% |
| 2% | 17% |
| 3% | 18% |
| 4% | 20% |
| 5% | 21% |
Want more companies with a valuation profile/forecast similar to that of Sanofi? See PRAH, UNH, REGN, CMD, and DXCM.
Loading social stream, please wait...